ANN ARBOR, Mich.—Compendia Bioscience and Althea Diagnostics recently announced that they will develop a product and service offering called the Breast Cancer Segregation Panel as a platform for companion diagnostic development. The panel measures 96 genes that represent key molecular variability of breast cancer and have been derived from a proprietary meta-analysis of cancer genomic profiles from more than 5,000 clinical samples. The assay has been optimized by Althea to measure the genes using quantitative RT-PCR from formalin-fixed tissue (FFPE) samples to enable rapid translation to real-world clinical settings. Compendia will analyze the data generated by the assay and perform correlation studies to end-points of interest such as drug response, allowing for development of multiple drug-specific companion diagnostics from a standardized platform. The companies also plan to develop similar assays for other cancer disease types.